Aranesp and Periactin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Aranesp (darbepoetin alfa) and Periactin (cyproheptadine hydrochloride). Common drug interactions include anhedonia among females and neutropenia among males.

The phase IV clinical study analyzes what interactions people have when they take Aranesp and Periactin. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Aranesp?

Aranesp has active ingredients of darbepoetin alfa. It is often used in anemia. eHealthMe is studying from 54,331 Aranesp users. Check the latest studies of Aranesp.

What is Periactin?

Periactin has active ingredients of cyproheptadine hydrochloride. It is often used in migraine. eHealthMe is studying from 2,214 Periactin users. Check the latest studies of Periactin.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 02, 2026

12 people who take Aranesp and Periactin together, and have interactions are studied.

Aranesp and Periactin drug interactions.

What are the common drug interactions of Aranesp and Periactin, by gender? *:

female:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Arterial thrombosis limb (formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system-limb)
  4. Cholecystitis (infection of gallbladder)
  5. Emotional distress
  6. Gallbladder injury
  7. General physical health deterioration (weak health status)
  8. Injury
  9. Malignant neoplasm progression (cancer tumour came back)
  10. Pain

male:

  1. Neutropenia (an abnormally low number of neutrophils)
  2. Pleural effusion (water on the lungs)
  3. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  4. Renal impairment (severely reduced kidney function)
  5. Tibia fracture (fracture of lower leg bone)
  6. Vitamin b12 decreased
  7. Wheezing (a high-pitched whistling sound made while you breath)
  8. Blood glucose increased
  9. Emotional distress
  10. Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs)

What are the common drug interactions of Aranesp and Periactin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Arterial thrombosis limb (formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system-limb)
  4. Cholecystitis (infection of gallbladder)
  5. Emotional distress
  6. Gallbladder injury
  7. General physical health deterioration (weak health status)
  8. Injury
  9. Pain
  10. Renal failure (kidney dysfunction)

40-49:

  1. Anaemia (lack of blood)
  2. Ankle fracture
  3. Chronic kidney disease
  4. Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
  5. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  6. Renal impairment (severely reduced kidney function)
  7. Tibia fracture (fracture of lower leg bone)
  8. Vitamin b12 decreased
  9. Wheezing (a high-pitched whistling sound made while you breath)
  10. Emotional distress

50-59:

  1. Neutropenia (an abnormally low number of neutrophils)
  2. Hypovolaemia (a decreased volume of circulating blood in the body)
  3. Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)
  4. Activated partial thromboplastin time prolonged
  5. Bacteria stool identified
  6. Blood alkaline phosphatase increased
  7. Culture stool positive
  8. Hepatic mass
  9. International normalised ratio increased
  10. Metastases to liver (cancer spreads to liver)

60+:

  1. Malignant neoplasm progression (cancer tumour came back)

What are the existing conditions these people have? *

  1. Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 5 people, 41.67%
  2. Hiv Infection: 2 people, 16.67%
  3. Gout (uric acid crystals building up in the body): 2 people, 16.67%
  4. Anaemia (lack of blood): 2 people, 16.67%
  5. Premenstrual Syndrome: 1 person, 8.33%
  6. Metastases To Liver (cancer spreads to liver): 1 person, 8.33%
  7. Diabetes: 1 person, 8.33%
  8. Cytomegalovirus Infection: 1 person, 8.33%
  9. Cough: 1 person, 8.33%
  10. Colon Cancer: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Aranesp and Periactin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Aranesp and Periactin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Aranesp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Periactin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Aranesp and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Periactin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on darbepoetin alfa and cyproheptadine hydrochloride (the active ingredients of Aranesp and Periactin, respectively), and Aranesp and Periactin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: